EUVIMEDScopri EUVIMED
Open access

Tumor immune microenvironment alterations associated with progression in human intraductal papillary mucinous neoplasms

Kevin T Jamouss iD, Alexander Ioannis Damanakis, Abigail C Cornwell iD, Martine Jongepier, Maria A Trujillo, Michael Johannes Pflüger iD, Ryan Kawalerski, Alexandre Maalouf, Katsuya Hirose, Shalini Datta, Abigail Sipes, Brian A Pedro iD and 7 more

The Journal of Pathology · 2025

DOI: 10.1002/path.6402 ↗

At a glance

Journal article in The Journal of Pathology, 2025. Written by Kevin T Jamouss and 18 co-authors. Institution: Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Major MEDLINE topics: Tumor Microenvironment, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Pancreatic Intraductal Neoplasms. Cited 9 times so far (Crossref); 39 references. The full text is freely available in PubMed Central. Funded by: IPMN Global Foundation, The Gerald O Mann Charitable Foundation, AACR-Bristol-Myers Squibb Midcareer Female Investigator.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Pancreatic ductal adenocarcinoma (PDAC) poses a significant challenge due to late‐stage diagnoses. To improve patient outcomes, early intervention in precursor lesions such as intraductal papillary mucinous neoplasm (IPMN) is crucial. However, early intervention must be balanced against overtreatment of low‐risk lesions that are unlikely to progress, underscoring the need to better understand molecular alterations in neoplastic cells and changes in the tumor microenvironment (TME) that drive the progression of IPMNs. In this study, we characterized alterations in the TME of IPMNs as they progressed to high‐grade dysplasia, using immunohistochemistry to quantify immune cell density and activation status in more than 100 well‐characterized human IPMN samples. Analyses revealed progression to a more immunosuppressive TME in high‐grade IPMN compared with low‐grade IPMN, characterized by elevated expression of immune checkpoint molecules (PD‐L1, TIM3, VISTA), increased density of macrophages, and decreased density of cytotoxic T cells. Intriguingly, the alterations in macrophages were limited to focal regions of high‐grade dysplasia, while T‐cell alterations affected the entire IPMN. Additionally, elevated VISTA expression was associated with poorer clinical outcome after IPMN resection in an independent cohort. These findings provide important insights into the interplay between the immune microenvironment and IPMN progression, highlighting potential targets to modify the TME for cancer interception. © 2025 The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

Tumor MicroenvironmentPancreatic NeoplasmsCarcinoma, Pancreatic DuctalPancreatic Intraductal NeoplasmsAdenocarcinoma, MucinousHumansDisease ProgressionMaleFemaleAgedMiddle AgedBiomarkers, TumorLymphocytes, Tumor-Infiltrating

Author keywords

cancer immunologyimmune checkpointimmune evasionimmunosuppressive microenvironmentintraductal papillary mucinous neoplasmlymphocyte infiltrationpancreatic ductal adenocarcinomatumor heterogeneitytumor immune microenvironmenttumor progression

Substances

Biomarkers, Tumor

Authors and institutions

  • Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Graduate School of Life Sciences, Utrecht University, Utrecht, The Netherlands.
  • Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Department of Physiology, University of Maryland, Baltimore, MD, USA.
  • Department of Pathology, University of Florida, Gainesville, FL, USA.

ORCID profiles: Kevin T Jamouss, Abigail C Cornwell, Michael Johannes Pflüger, Brian A Pedro, Laura D Wood

Funding

  • IPMN Global Foundation
  • The Gerald O Mann Charitable Foundation
  • AACR-Bristol-Myers Squibb Midcareer Female Investigator
  • Buffone Family Gastrointestinal Cancer Research Fund
  • Rolfe Pancreatic Cancer Foundation
  • NCI NIH HHS
  • NIGMS NIH HHS
  • Sol Goldman Pancreatic Cancer Research Center

Cite

APA

Jamouss, K. T., Damanakis, A. I., Cornwell, A. C., Jongepier, M., Trujillo, M. A., Pflüger, M. J., Kawalerski, R., Maalouf, A., Hirose, K., Datta, S., Sipes, A., Pedro, B. A., Gudmundsson, E., Assarzadegan, N., Engle, L., Scharpf, R. B., Kawamoto, S., Thompson, E. D., & Wood, L. D. (2025). Tumor immune microenvironment alterations associated with progression in human intraductal papillary mucinous neoplasms. The Journal of Pathology. https://doi.org/10.1002/path.6402

Vancouver

Jamouss KT, Damanakis AI, Cornwell AC, Jongepier M, Trujillo MA, Pflüger MJ, et al. Tumor immune microenvironment alterations associated with progression in human intraductal papillary mucinous neoplasms. The Journal of Pathology. 2025. doi:10.1002/path.6402

BibTeX
@article{Jamouss2025,
  author = {Jamouss, Kevin T and Damanakis, Alexander Ioannis and Cornwell, Abigail C and Jongepier, Martine and Trujillo, Maria A and Pflüger, Michael Johannes and Kawalerski, Ryan and Maalouf, Alexandre and Hirose, Katsuya and Datta, Shalini and Sipes, Abigail and Pedro, Brian A and Gudmundsson, Emma and Assarzadegan, Naziheh and Engle, Logan and Scharpf, Robert B and Kawamoto, Satomi and Thompson, Elizabeth D and Wood, Laura D},
  title = {Tumor immune microenvironment alterations associated with progression in human intraductal papillary mucinous neoplasms},
  journal = {The Journal of Pathology},
  year = {2025},
  doi = {10.1002/path.6402}
}
Start for free →